Current phase II antibody-drug conjugates for the treatment of lymphoid malignancies

Expert Opinion on Investigational Drugs

Volumn 23, Issue 7, 2014, Pages 911-924

  Robak, Tadeusz ^a   Robak, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

A dmDT390 bisFv; Brentuximab vedotin; Combotox; DCDT2980S; DCDTS4501A; Indatuximab ravtansine; Inotuzumab ozogamicin; Lorvotuzumab mertansine; Milatuzumab dox; Moxetumomab pasudotox; SAR 3419

Indexed keywords

BRENTUXIMAB VEDOTIN; CALICHEAMICIN; CD22 ANTIGEN; COMBOTOX; CYTOTOXIC AGENT; IMMUNOTOXIN; IMMUNOTOXIN LMB2; INDATUXIMAB RAVTANSINE; INOTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; MONOCLONAL ANTIBODY; MOXETUMOMAB PASUDOTOX; RG 7593; RG 7596; SAR 3419; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; COUGHING; DIARRHEA; DRUG CONJUGATION; DRUG EFFECT; DRUG HALF LIFE; DRUG RESEARCH; DYSPNEA; EDEMA; FATIGUE; FEVER; HAIRY CELL LEUKEMIA; HEADACHE; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; LYMPHATIC LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; REVIEW; SENSORY NEUROPATHY; T CELL LYMPHOMA; THROMBOCYTOPENIA; VOMITING; ANIMAL; CLINICAL TRIAL (TOPIC); LEUKEMIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA;

EID: 84902317441     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.908184     Document Type: Review

References (77)

1. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-69
2. Leslie LA, Younes A. Antibody-drug conjugates in hematologic malignancies. Am Soc Clin Oncol Educ Book 2013. [Epub ahead of print]
3. Robak T. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncol 2013;9:69-91
4. Polakis P. Arming antibodies for cancer therapy. Cur Opin Pharmacol 2005;5:382-7 (Pubitemid 40932040
5. Erickson HK, Wayne C. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody - maytansinoid conjugates. Bioconjug Chem 2010;21:84-92
6. Ricart AD, Tolcher AW. Technology insight: Cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 2007;4:245-55 (Pubitemid 46510534
7. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-37 (Pubitemid 46706511
8. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65 (Pubitemid 43980544
9. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71:6300-9
10. Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 2011;20:75-85
11. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013;76:248-62
12. Traynor K. Ado-trastuzumab emtansine approved for advanced breast cancer. Am J Health Syst Pharm 2013;70:562
13. Pezzutto A, Rabinovitch PS, Dorken B, et al. Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. J Immunol 1988;140:1791-5
14. Law CL, Aruffo A, Chandran KA, et al. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. J Immunol 1995;155:3368-76
15. Wong BY, Dang NH. Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 2010;10:1251-8
16. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumabozogamicin, a novel immunoconjugate for the treatment of Bcell non-Hodgkin's lymphoma: Results of a phase I study. J Clin Oncol 2010;28:2085-93
17. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. Lancet Oncol 2012;13:403-11
18. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumabozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119:2728-36
19. Ogura M, Hatake K, Ando K, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/ refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2012;103:933-8
20. Jain N, O'Brien S, Thomas DA, et al. Inotuzumab ozogamicin in combination (Mini-hyper-CVD) as frontline therapy for older patients (‡60 years) with acute lymphoblastic leukemia (ALL). Blood 2013;122:1432
21. Kreitman RJ, Pastan I. Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398-405
22. Park JH, Levine RL. Targeted immunotherapy for hairy cell leukemia. J Clin Oncol 2012;30:1888-90
23. Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxinmoxetumomabpasudotox (CAT-8015 or HA22) in patients with hairy cellleukemia. J Clin Oncol 2012;30:1822-8
24. Ravandi FH, Kantarjian HM, Goswami T, et al. Design of a phase 1/2 study of moxetumomab pasudotox in adult patients with relapsed and/or refractory acute lymphoblastic leukemia (ALL). Blood 2013;122:5021
25. Li D, Poon KA, Yu SF, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther 2013;12:1255-65
26. Advani R, Lebovic D, Brunvand M, et al. A Phase I study of DCDT2980S, an antibody-drug conjugate (ADC) targeting CD22, in relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts); Atlanta; 2012;120:abstract 59
27. Polson AG, Williams M, Gray AM, et al. Anti-CD22-MCC-DM1: An antibody-drug conjugate with a stable linker for the treatment of non- Hodgkin's lymphoma. Leukemia 2010;24:1566-73
28. Advani R, Chen AI, Lebovic D, et al. Final results of a phase I study of the anti-CD22 antibody-drug conjugate (ADC) DCDT2980S with or without rituximab (RTX) in patients (Pts) with relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma (NHL). Blood 2013;122:4399
29. Panowksi S, Bhakta S, Raab H, et al. Site-specific antibodydrug conjugates for cancer therapy. MAbs 2014;6:34-45
30. Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylatedricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000;6:1302-13 (Pubitemid 30226212
31. Herrera L, Farah RA, Pellegrini VA, et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000;14:853-8 (Pubitemid 30235063
32. Ghetie MA, Tucker K, Richardson J, et al. The antitumor activity of an anti- CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992;80:2315-20
33. Herrera L, Bostrom B, Gore L, et al. A phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009;31:936-41
34. Schindler J, Gajavelli S, Ravandi F, et al. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 2011;154:471-6
35. Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000;6:1302-13 (Pubitemid 30226212
36. Blanc V, Bousseau A, Caron A, et al. SAR3419: An anti-CD19-maytansinoid immune conjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011;17:6448-58
37. Raufi A, Ebrahim AS, Al-Katib A. Targeting CD19 in B-cell lymphoma: Emerging role of SAR3419. Cancer Manag Res 2013;5:225-33
38. Lutz RJ, Zuany-Amorim C, Vrignaud P, et al. Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immune conjugate, for the treatment of B-cell lymphoma. Proc Am Assoc Cancer Res 2006;47:3731
39. Younes A, Gordon LI, Kim S, et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30:2776-82
40. Coiffier B, Ribrag V, Dupuis J, et al. Phase I/II study of the anti-CD19 maytansinoidimmunoconjugate SAR3419 administered weekly to patients with relapsed/refractory B-cell non- Hodgkin's lymphoma (NHL). J Clin Oncol 2011;29(Suppl):8017
41. Coiffier B, Thieblemont C, de Guibert S, et al. Phase II study of anti-CD19 antibody drug conjugate (SAR3419) in combination with rituximab: Clinical activity and safety in patients with relapsed/refractory diffuse large B-cell lymphoma (NCT01470456). Blood 2013;122:4395
42. Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin Cancer Res 2000;6:693-700 (Pubitemid 30111495
43. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1622-36 (Pubitemid 30220540
44. Palanca-Wessels MC, Flinn IW, Sehn LH, et al. A phase I study of the anti-CD79b antibody-drug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non- Hodgkin's lymphoma (NHL) ASH. Blood (ASH Annual Meeting Abstracts); Atlanta; 2012;120:abstract 56
45. Palanca-Wessels MC, Salles GA, Czuczman MS, et al. Final results of a Phase I study of the anti-CD79b antibody-drug conjugate DCDS4501A in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Blood 2013;122:4400
46. Schirrmann T, Steinwand M, Wezler X, et al. CD30 as a therapeutic target for lymphoma. BioDrugs 2014;Apr;28(2):181-209
47. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study. Lancet Oncol 2013;14:1348-56
48. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
49. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximabvedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9
50. Gopal AK, Chen R, Smith SE, et al. Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximabvedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2013;122:4382
51. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31:1970-6
52. Pro B, Advani R, Bartlett NL, et al. Brentuximabvedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: Results of a phase 2 study. J Clin Oncol 2012;30:2190-6
53. Pro B, Advani RH, Brice P, et al. Three-year survival results from an ongoing phase 2 study of brentuximabvedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2013;122:1809
54. Bartlett NL, Sharman JP, Oki Y, et al. A Phase 2 study of brentuximabvedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: Interim results in patients with DLBCL and other B-cell lymphomas. Blood 2013;122:848
55. Woo JH, Lee YJ, Neville DM, Frankel AE. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials. Methods Mol Biol 2010;651:157-75
56. Woo JH, Bour SH, Dang T, et al. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1). Cancer Immunol Immunother 2008;57:1225-39
57. Woo JH, Liu JS, Kang SH, et al. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/ II clinical trials. Protein Expr Purif 2008;58:1-11
58. Frankel AE, Zuckero SL, Mankin AA, et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Curr Drug Targets 2009;10:104-9
59. Frankel AE. Anti-CD3 immunotoxin to induce remissions in cutaneous T-cell lymphoma patients. J Clin Oncol 2012;30:abstract 2505
60. Ishitsuka K, Jimi S, Goldmacher VS, et al. Targeting CD56 by the maytansinoidimmunoconjugate IMGN901 (huN901-DM1): A potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol 2008;141:129-31 (Pubitemid 351347531
61. Lutz RJ, Whiteman KR. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009;1:548-51
62. Ikeda H, Hideshima T, Fulciniti M, et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009;15:4028-37
63. Tassone P, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytansinoidimmunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004;104:3688-96 (Pubitemid 39564446
64. Jagannath S, Chanan-Khan A, Heffner LT, et al. BT062, an antibodydrug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma. Blood 2011;118:abstract 305
65. Heffner LT, Jagannath S, Zimmerman TM, et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: Sfety and further evidence of clinical activity. Blood 2012;120:abstract 4042
66. Kelly KR, Chanan-Khan A, Somlo G, et al. Indatuximab ravtansine (BT062) in combination with lenalidomide and lowdose dexamethasone in patients with relapsed and/or refractory multiple myeloma: Clinical activity in len/dexrefractory patients. Blood 2013;122:758
67. Berdeja JG. Lorvotuzumab mertansine: Antibody-drug-conjugate for CD56+ multiple myeloma. Front Biosci (Landmark Ed) 2014;19:163-70
68. van de Donk NW, Lokhorst HM. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother 2013;14:1569-73
69. Chari RV. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107
70. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res 1992;52:127-31
71. Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J 2012;14:799-805
72. Issell BF, Crooke ST, et al Cancer Treet Rev 1978;5:199-207
73. Chanan-Khan A, Wolf J, Garcia J, et al. Efficacy analysis from a phase I study of lorvotuzumab mertansine (IMGN901) used as monotherapy in patients with heavily pre-treated CD56-positive multiple myeloma. Blood 2010;116:819; abstract 1962
74. Berdeja JG, Hernandez-Ilizaliturri F, Chanan-Khan A, et al. Phase I study of lorvotuzumabmertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). J Clin Oncol 2011;29(Suppl):abstract 8013
75. Sapra P, Stein R, Pickett JQ, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005;11:5257-64 (Pubitemid 41003714
76. Stein R, Griffiths GL, Cardillo T, et al. Therapeutic activity of a new antibodydrug immunoconjugate, IMMU-110, in preclinical studies targeted against multiple myeloma. J Clin Oncol 2004;22(Suppl):6535
77. Govindan SV, Cardillo TM, Sharkey RM, et al. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 2013;12:968-78.